SOTIO to Present New Data on the IL-15 Superagonist SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors
PRAGUE, Czech Republic, November 04, 2020 / B3C newswire / -- SOTIO, a clinical stage immuno-oncology company, and Cytune Pharma, both owned by PPF Group, today announced that they will present a late breaking poster highlighting new clinical data on SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting to be held virtually November 9-14, 2020. SO-C101 is an IL-15 superagonist currently being investigated in a Phase 1 trial for the treatment of advanced solid tumors. Two additional posters will also be presented summarizing the latest preclinical data on SO-C101.
Late breaking poster details:
Title: A multicenter open-label phase 1/1b study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors Poster Number: 807 Session: In-Progress Clinical Trials Presenting Author: Aurélien Marabelle, M.D., Ph.D. Date/ Time: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13 from 4:40-5:10 p.m. EST
Poster presentation details:
Title: Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys Poster Number: 563 Session: Immune-stimulants and immune modulators Presenting Author: Irena Adkins, Ph.D. Date/ Time: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13 from 4:40-5:10 p.m. EST
Title: SO-C101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity Poster Number: 562 Session: Immune-stimulants and immune modulators Presenting Author: Irena Adkins, Ph.D. Date/ Time: Thursday, November 12, from 4:50-5:20 p.m. EST and Saturday, November 14 from 1:00-1:30 p.m. EST
Selected presentation materials will be made available on the SOTIO website once the presentations conclude.
Cytune Pharma is responsible for the clinical development of SO-C101 and SOTIO is a sponsor of the Phase 1 clinical trial.
About SOTIO SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.
SOTIO is a registered trademark of SOTIO a.s. in selected countries.
Contacts
Company contact Richard Kapsa Head of Communication T: (+420) 224 174 448 M: (+420) 603 280 971 kapsa@sotio.com
Media contact Kirsten Frazer, Ph.D. LifeSci Communications +1 646-863-0222 kfrazer@lifescicomms.com
Keywords: Humans; Clinical Trials, Phase I as Topic; Medical Oncology; IL15 protein, human; Interleukin-15; Receptors, Interleukin-15; Melanoma; Neoplasms; Immunotherapy; pembrolizumab; Immunoconjugates; Antibody-Dependent Cell Cytotoxicity; Antibodies, Monoclonal; Humanized; Immunologic Factors; Killer Cells, Natural; Longitudinal Studies
Published by B3C newswire
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
